Insulet Corporation (PODD) fundamentals score
Insulet Corporation is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 8.5 out of 10, Strong long-term fundamentals
- Growth: 8.4/10
- Profitability: 7.3/10
- Financial health: 9.4/10
- Earnings quality: 9.3/10
- Valuation: 8.8/10
Scores are calculated from Insulet Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Globus Medical, Inc. (GMED): 8.4/10